

PRESS RELEASE

THE EVOLUTIS GROUP ANNOUNCES AN INVESTMENT FROM TECHLIFE CAPITAL ACCOMPANIED BY ADAXTRA CAPITAL: A NEW STAGE IN THE ACCELERATION OF THE GROUP'S DEVELOPMENT

Briennon, France, July 24th, 2023 – **The EVOLUTIS Group, an international expert in the design and manufacturing of orthopedic joint implants for the hip, shoulder, knee and hand, announces that TECHLIFE CAPITAL, the investment fund specializing in the health and technology sectors, has invested in the company, in association with ADAXTRA Capital.** This strategic transaction represents a major step forward for the Lyons area based company and opens new prospects for its future development.

The EVOLUTIS Group, with consolidated sales of over €40 million in 2022 and a steady growth above 10%, generates almost 40% of its sales internationally and relies on a network of 45 distributors and three sales subsidiaries in France (Paris), Italy (Bologna) and India (Mumbai). Its expertise, sense of innovation, quality of production and controlled development have enabled the group to occupy a respected position in the orthopaedic prostheses market, particularly for the hip and shoulder, since it was founded in 1999 by Jean-Michel Peguet, Gérard Péliesson and Alain Meyer. These three visionaries were driven by one conviction: to put engineering and innovation at the service of patients' well-being. It's a vision that the group, which now employs nearly 200 people, shares with the TECHLIFE CAPITAL investment fund and ADAXTRA Capital.

Jean-Michel Peguet, Chairman of the EVOLUTIS Group, comments:

"We are delighted to announce this new phase in our journey with TECHLIFE CAPITAL, the growth fund dedicated to healthcare and technology, accompanied by ADAXTRA Capital. Their strong network of relationships and financial resources will enable us to accelerate our growth in particular internationally and offer a wider range of products and services to our customers. We remain fully committed to our mission and core values and look forward to working closely with TECHLIFE CAPITAL and ADAXTRA Capital to achieve further milestones in the development of the EVOLUTIS Group."

Jacques Rossignol, Managing Partner of TECHLIFE CAPITAL, declares :

"The orthopaedic prostheses sector is growing steadily worldwide, both in developed countries, where product and surgical innovations are making less invasive operations possible, and in developing countries, where the middle classes are expanding. This is a sector in which innovative French players such as the EVOLUTIS Group enjoy a high international reputation, backed up by the renown of the French school of orthopaedic surgery. We are delighted to invest in this expert and in its production site based in France, and to support the EVOLUTIS Group in accelerating its development, with a strong focus on patient well-being, innovation, exports and sustainable growth."

François Parmentier, Managing Director, Thibaut Penhoat and Grégory Lecomte, Investment Directors of ADAXTRA Capital, add : *"We are particularly enthusiastic about the prospect of working with such a high-quality management team and with TECHLIFE CAPITAL. The dynamic of the sector where the EVOLUTIS Group is focused, its positioning and its capabilities give us great confidence in the company's development potential."*

The EVOLUTIS Group specializes in orthopedic solutions for the hip, shoulder, knee and hand, and has grown steadily since its creation in 1999, accelerating sharply in recent years. The group has 3 sales subsidiaries in France (Paris), Italy (Bologna) and India (Mumbai), and a network of over 45 distributors worldwide. By 2022, it had consolidated sales of over €40 million, with a workforce of almost 200.

More information can be found on www.evolutisfrance.com

TECHLIFE CAPITAL I is a growth equity fund specialising in the healthcare and technology industries, where it proactively identifies promising sector verticals that it investigates in depth (orthopaedic prostheses, essential medicines, cancer diagnostics, healthcare data management, biotech services, etc.). It then helps to structure these sectors by selecting and supporting ambitious companies in their transformation into European or even global leaders. TECHLIFE CAPITAL SAS is a management company approved by the French Autorité des Marchés Financiers, and has been awarded the Tibi label for Innovation Financing by the French Ministry of the Economy. EVOLUTIS is TECHLIFE CAPITAL's 8th investment after XPATH (cancer diagnostic services), FLASH THERAPEUTICS (production of biotechnological drugs for biotechs), MYDATA TRUST (patient data management for biotechs), MITEM PHARMA (pharmaceutical laboratory dedicated to Drugs of Major Therapeutic Interest), QUINTEN (AI and data science solutions for pharmaceutical laboratories), MAXXING (SaaS customer loyalty software) and CNSI (e-commerce solutions).

More information can be found on www.techlifecapital.com

ADAXTRA Capital, a French private equity firm, manages close to €450 million in assets on behalf of more than 500 clients. With expertise in supporting talented entrepreneurs and investing in private market funds, ADAXTRA Capital offers its clients a wide range of investment opportunities. The team, made up of experienced individuals with complementary multi-sector skills, is particularly sensitive to the human values of the managers it supports. Its aim is to build long-term partnerships based on trust and respect. ADAXTRA Capital is a subsidiary of BRED Banque Populaire.

More information on <https://adaxtra.com>

Grégory FOUR – Marketing Project Manager at Evolutis / 06 29 94 92 59 – four@evolutis42.com

Alexandra CHAMPAILLER – Human Resources Director at Evolutis / 06 17 02 85 80 - champailler@evolutis42.com